Esperion Therapeutics, Inc. (ESPR) News
Filter ESPR News Items
ESPR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ESPR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ESPR News From Around the Web
Below are the latest news stories about ESPERION THERAPEUTICS INC that investors may wish to consider to help them evaluate ESPR as an investment opportunity.
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.– Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease – ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe). The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with: P |
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare ConferenceANN ARBOR, Mich., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET). The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website |
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt – – New Facility Represents $150 Million Strategic Investment Led by Healthcare Specialist Athyrium Capital Management and Joined by HealthCare Royalty – ANN ARBOR, Mich., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has closed on a series of financing transactions that will support the Company’s |
Esperion Announces $210 Million Convertible Debt FinancingANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreements”) with certain holders of its outstanding 4.00% Convertible Senior Subordinated Notes due 2025 (the “2025 Notes”). Pursuant to the Agreements, Esperion will issue $100 million aggregate principal amount of its 5.75% Convertible Senior Subordinated Notes due 2030 (the “New Notes”) consisting of ( |
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing Pharmaceutical Products for More Than 80 Years – ANN ARBOR, Mich., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® ( |
ESPR Files New Drug Submissions for Nexletol & Nexlizet in CanadaEsperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and cardiovascular risk. Shares rise. |
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular RiskANN ARBOR, Mich., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has filed New Drug Submissions (NDSs) to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications that reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. "These submissions mark another pivotal milestone towards bringing our potentially lifesaving medications to the millions of patients around the world who need it,” said Sheldon Koenig, |
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of HypercholesterolemiaANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for the manufacture and sale of bempedoic acid in Japan for the treatment of hypercholesterolemia and familial hypercholesterolemia. Bempedoic acid has a novel mechanism of action that inhibits a cholesterol synthesis pathway by acting on ATP (adenosine triphospha |
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare ConferenceANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 12:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for appr |
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo – ANN ARBOR, Mich., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease (PAD) who were unable or unwilling to take statin medications. These data were presented today in an oral featured science presentation |